Post Tags

Currently displaying posts matching the tag


  • 2017 Scientific Symposium Wrap-Up

    Posted on 10/19/2017 1:28 PM

    On October 11, 2017, a Scientific Symposium was held at MMS in Canton, Michigan. The purpose of the Symposium was to discuss...

    View Post

  • MMS Hosts 2017 Scientific Symposium

    Posted on 10/10/2017 2:56 PM

    In keeping with our commitment to excel and develop colleagues and add value to the pharmaceutical industry, MMS will...

    View Post

  • Pfizer Selects MMS as Preferred Provider for Plain Language Summary Writing Support

    Posted on 9/26/2017 1:32 PM

    Pfizer has selected MMS Holdings Inc. (MMS), headquartered in Canton, MI, as a preferred provider for support writing plain language summaries of the results for all its Phase 2 and 3 clinical trials....

    View Post

  • MMS Case Study: Data Transparency & Anonymization Programming – Innovation at Work

    Posted on 4/22/2016 9:51 AM

    MMS Case Study: Data Transparency & Anonymization Programming – Innovation at Work. Read about the challenge, solution, and outcome to see how MMS could help your team!

    View Post

  • 4 Essentials to Colleague Recruitment and Retention in Pharma

    Posted on 2/15/2013 12:01 PM

    Employee turnover is costly. There is no industry in which that assertion holds more truth than the biotech industry. In this industry, the average cost of replacing an employee is roughly 50% more than the runner-up aerospace/defense industry.1 The obvious implication here is that turnover, particularly at a biotech company or a clinical research organization (CRO), should be kept to a minimum. Retaining quality employees should be a priority for any company (for many reasons, financial and oth

    View Post

  • Clinical Trial Disclosure: More “FDA” Needed in Past & Present Acts?

    Posted on 11/29/2012 9:54 AM

    Federal mandates calling for transparency of clinical trial information have been in place in the United States since 1997, but a recent move will finally give the current FDA (Food and Drug Administration) law some teeth to enforce compliance. In September, the US Department of Health & Human Services (HHS) transferred authority from HHS control to the FDA to oversee information that is filed to (“clinical trial registry data bank”), and seek out those who fail to file, o

    View Post

  • How to Build a Document Review Team: A Medical Writing Guide

    Posted on 10/11/2012 10:45 AM

    Whether it’s the completion of a clinical study report (CSR) for a clinical trial, or the completion of a submission document for a drug development program, medical writing represents the culmination of many people’s work over the course of many years. Due to the number of stakeholders involved across multiple functional areas, medical writing tends to be a consensus‑driven process, representing many contributor’s thoughts and ideas. Building the right review team can significantly contribute t

    View Post

  • Clinical Disclosure Reporting: Are You Prepared to Meet the Expanding Requirements?

    Posted on 9/7/2012 10:54 AM

    A group of House Democrats led by Congressman Edward Markey (D-Mass.) on Aug. 2 introduced the Trial and Experimental Studies Transparency (TEST) Act of 2012 (H.R. 6272), legislation that "updates and expands the clinical trial registry data bank——with stronger reporting requirements," according to a press release dated that same day (1). This proposed legislation is yet another step to address the increasing demand for greater transparency of clinical trial information. As we

    View Post

Regulatory Submission Support Based on Strong Science and Strength of Process. The difference is in the data!

Contact Us Today!